ABOUT US

Our Approach

Broadview is a mission-driven fund whose primary investment goal is to improve human health in the areas of cardiovascular disease and stroke. We define success – return on mission – as improving human health by bringing innovative technologies to patients. With 37 such investments over the past 9 years, Broadview has considerable experience in the seed/early-stage space, and its investment model is demonstrating early signs of success.

Our History

The mission and structure of Broadview Ventures can be traced to the Leducq Foundation and its supporting Trust, created in 1996 by French entrepreneur and industrialist Jean Leducq, together with his wife Sylviane. Motivated by a multi-generational family history of cardiovascular illness, and inspired to work at the international level through years of living and working abroad, the Leducqs established a foundation for cardiovascular research with a mission to improve human health through international efforts to combat cardiovascular and neurovascular disease.

In 2008, Broadview Ventures was then created to specifically address the translational gap by providing seed and early stage funding, via equity investments in companies developing innovative technologies for the diagnosis and treatment of cardiovascular disease and stroke.

Where We Invest

Broadview invests specifically in cardiovascular disease indications.

Cardiovascular Indications

  • Heart Disease
  • Peripheral Vascular Disease
  • Valvular Disorders
  • Hypertension and Cardio-Renal
  • Underlying pathways (e.g., inflammation, atherogenesis)

  • Obesity
  • Type II Diabetes
  • Metabolic Syndrome
  • Dyslipidemia
  • Peripheral vascular
  • Neurovascular

Technology Focus

Diversified across:

  • Therapeutics –  small molecules and biologics
  • Regenerative therapies –  cell and gene therapies
  • Devices –  implantable, interventional, and monitoring devices
  • Diagnostics –  stand-alone or companion diagnostics

Investment Stage

Early-Stage defined as:

  • Seed to Series B
  • Late pre-clinical through clinical proof-of-concept

*Pie chart represents our initial stage of investment

Our Process

Broadview Ventures reviews investment opportunities on a rolling basis. To be considered, please send us an executive summary of your company or technology. We will respond in 7-10 business days.